C9orf72 and amyotrophic lateral sclerosis: In the Phase 2 trial for ALS related to C9orf72 mutations, the primary objectives were safety, tolerability, pharmacokinetics, and pharmacodynamics, encompassing plasma and CSF PGRN levels and blood and CSF NfL concentrations as secondary outcomes.